On June 22, the U.S. Food and Drug Administration (FDA) approved Kengreal (cangrelor), an I.V. antiplatelet drug, for use in adults undergoing undergoing percutaneous coronary intervention (PCI). Read more.
FDA approves antiplatelet drug for use during PCI
Most Recent Content
For Nurse Practitioners
Do Vitamins, Plants Help Uterine Fibroid Risk or Treatment?
A research team out of Poland recently undertook a comprehensive examination of published data to determine the role that vitamins and diet might play...
